January 2017

New Product - Movapo

Movapo (apomorphine hydrochloride) is a directly acting dopamine receptor agonist, structurally related to dopamine. Movapo injection is indicated to reduce the number and severity of ‘off’ phases in patients with Parkinson’s disease severely disabled by motor fluctuations refractory to conventional therapy. Initiation of therapy with Movapo injection should be undertaken in a specialist unit in a hospital setting. Conventional therapy should be continued during ‘on’ phases. Movapo injection is contraindicated in patients with a known hypersensitivity or allergy to apomorphine, morphine or chemically related products. Movapo injection should not be administered to patients with pre-existing neuropsychiatric problems or dementias due to either pathological processes, e.g. Alzheimer’s disease, or to patients whose ‘on’ response to L-dopa is marred by severe dyskinesia, hypotonia or psychotoxicity. Movapo injection is also contraindicated in patients with inadequate renal or liver function, unstable coronary vascular disease, cerebrovascular disease, respiratory depression or CNS depression. Movapo injection is also contraindicated in patients with a known hypersensitivity to sodium metabisulfite. Movapo is available as a solution for injection for subcutaneous use only containing 20 mg/2 mL ( 2 mL ampoule) or 50 mg/ 5 mL (5 mL ampoule) apomorphine hydrochloride in packs of 5’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629